This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 24.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 900% and 3.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 2.16% and 2.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Services Stocks to Buy Amid Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most. However, staffing shortages may disrupt the trend.
Life Time Group Holdings, Inc. (LTH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Life Time Group Holdings, Inc. (LTH) delivered earnings and revenue surprises of 16.67% and 0.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Matches Q4 Earnings Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
OncoCyte (OCX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of 38.46% and 32.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for OncoCyte (OCX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Strength Seen in Cano Health, Inc. (CANO): Can Its 32.2% Jump Turn into More Strength?
by Zacks Equity Research
Cano Health, Inc. (CANO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why OncoCyte (OCX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
OncoCyte (OCX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
OncoCyte (OCX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of 46.15% and 17.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -114.29% and 8.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 12.50% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 2.51% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OncoCyte (OCX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of 15.38% and 16.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Tivity Health (TVTY) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Tivity Health (TVTY) delivered earnings and revenue surprises of -4.76% and 4.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Q4 Earnings Match Estimates, Revenues Lag (Revised)
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of 0% and -17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of -20% and 17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Tivity Health (TVTY) Lags Q4 Earnings Estimates
by Zacks Equity Research
Tivity Health (TVTY) delivered earnings and revenue surprises of -21.05% and 0.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LHC Group (LHCG) Q4 Earnings Lag Estimates
by Zacks Equity Research
LHC (LHCG) delivered earnings and revenue surprises of -4.55% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AMN Healthcare Services (AMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 14.34% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte (OCX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
OncoCyte (OCX) delivered earnings and revenue surprises of -57.14% and -69.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.